Neurological Biomarkers Market Expected to Reach $18.9 Billion by 2031 | Allied Market Research

WILMINGTON, DELAWARE, UNITED STATES, April 18, 2024 /EINPresswire.com/ -- size was valued at $5.4 billion in 2021, and is estimated to reach $18.9 billion by 2031, growing at a CAGR of 13.6% from 2022 to 2031. Ever-increasing rise in the incidence of Alzheimer’s and Parkinson’s is anticipated to contribute toward the robust growth of neurological biomarkers among these two applications. In addition, surge in adoption of neurological biomarkers in drug development and validation has increased over the years to improve the accuracy of clinical trials. Further, rise in transition toward personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimer’s and Parkinson’s.

𝐋𝐢𝐬𝐭 𝐨𝐟 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 :
Neurobio, bioMérieux, PERKINELMER INC., shimadzu corporation, Thermo Fisher Scientific, Inc., Quanterix, MYRIAD RBM (MYRIAD GENETICS, INC.), Bio-Rad Laboratories, Inc., merck kgaa, darmstadt, germany, F. HOFFMANN-LA ROCHE LTD.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/3555

On the basis of application of neurological biomarkers, the multiple sclerosis segment is expected to witness a significant CAGR during the forecast period. Rise in incidence rate of multiple sclerosis boot the growth of neurological biomarker market. For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

On the basis of region, Asia-Pacific is expected to witness highest CAGR during the forecast period in neurological biomarkers market forecast, owing to rise in geriatric population and the launch of various products in the region to fulfill the growing demands. Additionally, the development of human-induced pluripotent stem cells (iPS) for early diagnosis of Parkinson’s disease in Japan is a recent trend, which is being followed. In addition, the rise in population in Japan is on an increase and the number has reached to 126.26 million individuals as of 2019. Therefore, such increase in population which is more susceptible to Parkinson’s disease is anticipated to help supplement the neurological biomarkers industry growth.

𝐅𝐨𝐫 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲 https://www.alliedmarketresearch.com/purchase-enquiry/3555

However, the sales of neurological biomarkers product have witnessed hindrances, owing to the strict government regulations. The emerging ethical issues regarding early diagnosis of Alzheimer’s disease, Parkinson’s disease, and multiple Sclerosis is expected to impede the market growth. On the contrary, surge in healthcare investments in public as well as private sectors, increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer’s and Parkinson’s are anticipated to open new avenues for expansion of the neurological biomarkers market size during the forecast period.

𝐀𝐕𝐄𝐍𝐔𝐄- 𝐀 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐁𝐚𝐬𝐞𝐝 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 (𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐨𝐧-𝐝𝐞𝐦𝐚𝐧𝐝, 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧-𝐛𝐚𝐬𝐞𝐝 𝐩𝐫𝐢𝐜𝐢𝐧𝐠 𝐦𝐨𝐝𝐞𝐥) 𝐎𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 𝐀𝐥𝐥𝐢𝐞𝐝 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

𝐆𝐞𝐭 𝐚𝐧 𝐚𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐭𝐡𝐞 𝐥𝐢𝐛𝐫𝐚𝐫𝐲 𝐨𝐟 𝐫𝐞𝐩𝐨𝐫𝐭𝐬 𝐚𝐭 𝐚𝐧𝐲 𝐭𝐢𝐦𝐞 𝐟𝐫𝐨𝐦 𝐚𝐧𝐲 𝐝𝐞𝐯𝐢𝐜𝐞 𝐚𝐧𝐝 𝐚𝐧𝐲𝐰𝐡𝐞𝐫𝐞. 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬, 𝐟𝐨𝐥𝐥𝐨𝐰 𝐭𝐡𝐞 𝐥𝐢𝐧𝐤: https://www.alliedmarketresearch.com/library-access

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:
Neurological Biomarkers Market: https://www.alliedmarketresearch.com/neurological-biomarkers-market
Point of Care Diagnostics Market: https://www.alliedmarketresearch.com/point-of-care-diagnostics-market
Contraceptives Market: https://www.alliedmarketresearch.com/contraceptives-market
Electrophysiology Market: https://www.alliedmarketresearch.com/electrophysiology-devices-market

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

David Correa
Allied Market Research
+1 5038946022
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn